{"title":"治疗性单克隆抗体于2022年获得FDA批准","authors":"","doi":"10.33140/jcei.08.01.03","DOIUrl":null,"url":null,"abstract":"Compared with the annual record high, 17 therapeutic monoclonal antibodies (mAb) approved in 2017, this year total 16 therapeutic mAb were approved by FDA, interestingly 4 of them targeted at VEGF (Vascular Endothelial Growth Factor), two indicated for solid tumor, two for Neovascular (Wet) Age-Related Macular Degeneration [1]. Monoclonal antibody technique was created by Georges Köhler, César Milstein, and Niels Kaj Jerne in 1975 by using a mouse x mouse hybridoma. In 1984 they were awarded the Nobel Prize in Medicine for the discovery. Eight years later, in 1992 US FDA approved the first therapeutic mAb muromonab","PeriodicalId":73657,"journal":{"name":"Journal of clinical & experimental immunology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Therapeutic Monoclonal Antibodies Approved by FDA in 2022\",\"authors\":\"\",\"doi\":\"10.33140/jcei.08.01.03\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Compared with the annual record high, 17 therapeutic monoclonal antibodies (mAb) approved in 2017, this year total 16 therapeutic mAb were approved by FDA, interestingly 4 of them targeted at VEGF (Vascular Endothelial Growth Factor), two indicated for solid tumor, two for Neovascular (Wet) Age-Related Macular Degeneration [1]. Monoclonal antibody technique was created by Georges Köhler, César Milstein, and Niels Kaj Jerne in 1975 by using a mouse x mouse hybridoma. In 1984 they were awarded the Nobel Prize in Medicine for the discovery. Eight years later, in 1992 US FDA approved the first therapeutic mAb muromonab\",\"PeriodicalId\":73657,\"journal\":{\"name\":\"Journal of clinical & experimental immunology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of clinical & experimental immunology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33140/jcei.08.01.03\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of clinical & experimental immunology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33140/jcei.08.01.03","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
摘要
与2017年批准的17种治疗性单克隆抗体(mAb)的年度最高纪录相比，今年FDA共批准了16种治疗性mAb，有趣的是，其中4种针对VEGF(血管内皮生长因子)，2种用于实体瘤，2种用于新血管(湿)年龄相关性黄斑变性[1]。单克隆抗体技术是由Georges Köhler、csamar Milstein和Niels Kaj Jerne于1975年利用小鼠x小鼠杂交瘤发明的。1984年，他们因这一发现获得了诺贝尔医学奖。8年后的1992年，美国FDA批准了首个治疗性单抗
Therapeutic Monoclonal Antibodies Approved by FDA in 2022
Compared with the annual record high, 17 therapeutic monoclonal antibodies (mAb) approved in 2017, this year total 16 therapeutic mAb were approved by FDA, interestingly 4 of them targeted at VEGF (Vascular Endothelial Growth Factor), two indicated for solid tumor, two for Neovascular (Wet) Age-Related Macular Degeneration [1]. Monoclonal antibody technique was created by Georges Köhler, César Milstein, and Niels Kaj Jerne in 1975 by using a mouse x mouse hybridoma. In 1984 they were awarded the Nobel Prize in Medicine for the discovery. Eight years later, in 1992 US FDA approved the first therapeutic mAb muromonab
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
